๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Worsening after rituximab treatment in anti-mag neuropathy

โœ Scribed by Laura Broglio; Giuseppe Lauria


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
41 KB
Volume
32
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Rituximab in the treatment of polyneurop
โœ Susanne Renaud; Michael Gregor; Peter Fuhr; Delia Lorenz; Gรผnther Deuschl; Alois ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB

## Abstract No causative or curative therapy exists for the polyneuropathy associated with antibodies to myelinโ€associated glycoprotein (antiโ€MAG). Rituximab is a mouseโ€human chimeric antibody that specifically eliminates Bโ€cells and Bโ€cell precursors. Preliminary results suggest a beneficial effec

Anti-MAG and anti-SGPG antibodies in neu
โœ Leonard H. van den Berg; Arthur P. Hays; Eduardo Nobile-Orazio; Lawrence J. Kins ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 678 KB

We compared the binding of human antibodies from patients with neuropathy to the myelin-associated glycoprotein (MAG), to its cross-reactive glycolipid sulfoglucuronyl paragloboside (SGPG), and to sections of peripheral nerve. Titers were correlated with the clinical presentation and results of elec

Anti-SGPG antibody in CIDP: Nosological
โœ Yumi Tagawa; Nobuhiro Yuki; Koichi Hirata ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 152 KB

Polyneuropathy with monoclonal gammopathy usually is considered a nosological entity different from chronic inflammatory demyelinating polyneuropathy (CIDP). Criteria proposed by the American Academy of Neurology AIDS Task Force (1991), however, show monoclonal gammopathy to be a condition concurren